在高盛医疗健康大会上,默沙东首席执行官阐述了公司的未来并购战略,明确指出将把重点放在交易规模在10亿至150亿美元之间的“甜蜜点”上。这一战略定位旨在通过精准且规模适中的收购,有效补充和强化公司的产品管线,同时平衡风险与增长机遇。
在高盛医疗健康大会上,默沙东首席执行官阐述了公司的未来并购战略,明确指出将把重点放在交易规模在10亿至150亿美元之间的“甜蜜点”上。这一战略定位旨在通过精准且规模适中的收购,有效补充和强化公司的产品管线,同时平衡风险与增长机遇。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.